Becton, Dickinson and Company
HealthcareNYSE:BDX · New York Stock Exchange
-$1.11 today
Vol 1.60M · Avg 2.79M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
6.6%
avg 7.0%
ROIC
4.7%
avg 3.8%
ROA
3.0%
avg 2.7%
Analysis
ROE is currently the strongest return metric at 6.6% versus its period average of 7.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman | $3.59M | — | 53 | $108,235.00 | 0.03% |
Michael C. Feld | Executive VP & Chief Revenue Officer | $1.91M | — | 45 | $14,272.00 | <0.01% |
Vitor Roque | Executive Vice President & Chief Financial Officer | $1.78M | — | 43 | $8,231.00 | <0.01% |
Richard Byrd | Executive Vice President & President of Interventional Segment | $1.41M | — | 58 | $13,183.00 | <0.01% |
Michael Garrison | Executive VP & President of Medical Segment and BioPharma Systems Segments | $1.36M | — | 57 | $14,272.00 | <0.01% |
Meera Gopalakrishnan | Senior VP & Global Chief Marketing Officer | — | — | — | — | — |
Carla Burigatto | Senior Vice President & Chief Communications Officer | — | — | — | — | — |
Joseph Smith | Senior Vice President & Chief Scientific Officer | — | — | — | — | — |
Shawn C. Bevec | Senior Vice President of Investor Relations | — | — | — | — | — |
Claudia Curtis | Senior Vice President, Chief Ethics & Compliance Officer | — | — | — | — | — |
Denise Fleming | Executive Vice President & Chief Information Officer | — | — | 55 | — | — |
Elizabeth McCombs | Executive Vice President & Chief Technology Officer | — | — | 49 | — | — |
Pamela L. Spikner | Senior Vice President, Chief Accounting Officer & Controller | — | — | 49 | $3,323.00 | <0.01% |
Lanesha T. Minnix | Executive Vice President & General Counsel | — | — | 51 | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$1.01M
Sells
21
$1.92M
Net Sentiment
$910,887.09
Net selling
Most Active
Feld Michael
10 transactions
1–10 of 22
Analysis
Insiders reported 1 buys worth $1.01M and 21 sells worth $1.92M over the last 12 months. That adds up to net selling of $910,887.09. Feld Michael was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -15.7% | +11.2% (15yr)1 analysts |
| Revenue | N/A | N/A | +10.1% | +5.2% (15yr)4 analysts |
| Net Income | N/A | N/A | -15.9% | +13.7% (15yr)4 analysts |
| EBIT | N/A | N/A | -11.7% | +5.9% (15yr)4 analysts |
Analysis
Recent growth has been strongest in Revenue at +10.1% over three years. Forward estimates point to Net Income at +13.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
argenx SE
NASDAQ:ARGX
$55.29B
Cardinal Health, Inc.
NYSE:CAH
$52.43B
Edwards Lifesciences Corporation
NYSE:EW
$49.01B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.24B
Haleon plc
NYSE:HLN
$40.31B
Agilent Technologies, Inc.
NYSE:A
$36.67B
Alcon Inc.
NYSE:ALC
$32.58B
IQVIA Holdings Inc.
NYSE:IQV
$30.29B
ResMed Inc.
NYSE:RMD
$28.25B
Veeva Systems Inc.
NYSE:VEEV
$25.92B
Who manages BDX?
Becton, Dickinson and Company (BDX) lists 14 active executives. The top listed executive is Meera Gopalakrishnan, Senior VP & Global Chief Marketing Officer.
Are BDX insiders buying or selling?
Recent insider activity shows net buying of $52.48M.
Explore More
Continue the stock analysis
Jump to another research area for this company.